Loading...
•
Jul 01, 2023
USANA Q2 2023 Earnings Report
USANA reported second quarter results modestly ahead of internal expectations.
Key Takeaways
USANA Health Sciences reported a decrease in net sales to $238 million compared to $264 million in the second quarter of 2022, and diluted EPS was $0.89, down from $1.00 in the same period last year. The company updated its fiscal year 2023 net sales guidance to $900 to $950 million and diluted EPS guidance to $2.65 to $3.30.
Second quarter net sales reached $238 million, compared to $264 million in Q2 2022.
Diluted EPS for the second quarter was $0.89, versus $1.00 in the prior year's quarter.
The company is raising the lower end of its net sales and earnings per share outlook for fiscal year 2023.
USANA plans to open its 25th global market in India in late 2023.
Revenue by Geographic Location
Forward Guidance
The Company is raising the lower end of its net sales and earnings per share outlook for fiscal year 2023.
Positive Outlook
- Consolidated Net Sales guidance updated to $900 - $950 million.
- Diluted EPS guidance updated to $2.65 - $3.30.
- Planned initiatives for the remainder of the year provide confidence to raise the bottom-end of full year guidance.
- The company will continue investing in strategies designed to deliver sustainable long-term growth.
- Operating results in the second quarter of 2023 were modestly ahead of internal expectations due, in part, to a strong response to a local sales promotion offered in mainland China.
Challenges Ahead
- A large global promotion was offered in the second quarter of 2022, which did not reoccur in 2023 and created a difficult year-over-year comparison for the current year quarter.
- The first half of this year benefitted from certain discrete sales activity not expected to recur in the back half of the year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...